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Abstract  
Objective  To identify genetic determinants of 
inflammatory bowel disease (IBD), we examined an 
association between polymorphisms of both the 
programmed cell death 1 gene (PDCD1) and the src 
homology 2 domain-containing tyrosine phosphatase 2 
gene (PTPN11) and susceptibility to IBD. 
Methods  Study subjects comprised 114 patients with 
ulcerative colitis (UC), 83 patients with Crohn’s disease, and 
200 healthy control subjects. Five single nucleotide 
polymorphisms (SNPs) in PDCD1 and PTPN11 were detected 
by PCR-restriction fragment length polymorphism. 
Subsequently, haplotypes composed of the two SNPs in 
PTPN11 were constructed.  
Results  The frequencies of the Hap 1 haplotype and its 
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homozygous Hap 1/Hap 1 diplotype of PTPN11 were 
significantly increased in UC patients compared to control 
subjects (P = 0.011 and P = 0.030, respectively). While, no 
association was found for PDCD1 for UC or CD and none for 
PTPN11 for CD.  
Conclusion  PTPN11 is a genetic determinant for the 
pathogenesis of UC, and haplotyping of PTPN11 may be 
useful as a genetic biomarker to identify high-risk 
individuals susceptible to UC. 
 
Key words  
PTPN11; polymorphisms; ulcerative colitis; candidate 
gene-based association study; Japanese population 
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Introduction 
Chronic inflammatory bowel disease (IBD) is a 
multifactorial disorder characterized by inflammation 
specific to the gastrointestinal tract, resulting in intestinal 
malabsorption, immune system abnormalities, and an 
exaggerated T-cell response [1-3]. IBD consists of two main 
subtypes, ulcerative colitis (UC) and Crohn's disease (CD). 
Although the precise etiology of IBD remains unknown, 
several environmental factors, such as dietary components 
and microorganisms, and genetic factors may contribute to 
the occurrence of IBD [1-3]. Some genome-wide linkage 
analyses and candidate gene-based association studies with 
single nucleotide polymorphisms (SNPs), which focus on 
determining unknown genetic factors underlying the 
genetic determinants of the pathogenesis of IBD, have 
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identified possible IBD-susceptibility genes and 
chromosomal loci [4-6].   
 IBD is involved in a complex interplay of immune and 
inflammatory cells, including lymphocytes, macrophages, 
and dendritic cells [7-9]. In addition, the interaction 
between antigen-presenting cells and T-cells plays a crucial 
role in the pathogenesis of IBD. We have already found an 
association between a lack of susceptibility to UC in the 
Japanese population and a polymorphism of the cytotoxic 
T-lymphocyte antigen 4 gene (CTLA4) [10], which expresses 
only on activated T-cells as an immunoreceptor. During 
antigenic stimulation of T-cells, CTLA4 downregulates 
T-cell activation after binding to B7-1 (CD80) and B7-2 
(CD86) [11-14]. As another immunoreceptor of the 
CD28/CTLA4 family, programmed cell death 1 (PD-1) is also 
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expressed on T-cells, as well as B-cells and myeloid cells. 
PD-1 negatively signals T-cell activation and tolerance 
through the interaction of its specific ligands, PD-L1 or 
PD-L2 [13-15]. Moreover, polymorphisms of the PD-1 gene 
(PDCD1) are associated with susceptibility to autoimmune 
diseases, including systemic lupus erythematosus [16-18], 
rheumatoid arthritis [19,20], and multiple sclerosis [21] in 
the Caucasian and Chinese populations. 
 Conversely, the inhibitory signals of both CTLA4 and 
PD-1 are mediated, at least in part, by the interaction with 
src homology 2 domain-containing tyrosine phosphatase-2 
(SHP-2), which plays a key role in the intracellular signaling 
elicited by a number of growth factors, hormones, and 
cytokines during development and hematopoiesis 
[15,22-25]. In addition, germline mutations of PTPN11 
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encoding SHP-2 cause Noonan and LEOPARD syndromes 
[26-28], as well as somatic mutations in acute myeloid 
leukemia [29]. Moreover, an intronic polymorphism of 
PTPN11, but not exonic mutations, is associated with gastric 
atrophy in Japanese subjects infected with cagA-positive 
Helicobacter pylori [30].   
 Despite the importance of the regulatory functions of 
PD-1 and SHP-2, no systemic studies have been reported on 
the association of genetic polymorphisms of PDCD1 and 
PTPN11 with IBD in the Japanese population or in other 
populations. Therefore, we investigated whether SNPs and 
their combination polymorphisms, referred to as 
haplotypes, in PDCD1 and PTPN11 are associated with IBD 
susceptibility in the Japanese population, and whether SNPs 
can be used as new genetic biomarkers for predicting the 
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onset of IBD. 
 
Subjects and Methods   
Subjects   
The study subjects were all Japanese and unrelated, 
consisting of 114 patients with UC, 83 patients with CD, and 
200 gender-matched, healthy volunteers as control subjects. 
The characteristics of the subjects are shown in Table I. IBD 
patients were enrolled from eight general health clinics in 
Nagasaki, Japan. The study protocol was approved by the 
Committee for Ethical Issues dealing with the Human 
Genome and Gene Analysis at Nagasaki University, and 
written informed consent was obtained from each subject. 
The diagnosis of IBD was made on the basis of 
endoscopic, radiological, histological, and clinical criteria 
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of both the World Health Organization Council for 
International Organizations of Medical Sciences and the 
International Organization for the Study of Inflammatory 
Bowel Disease [31,32]. Patients with indeterminate colitis, 
multiple sclerosis, systemic lupus erythematosus, or other 
diagnosed autoimmune diseases were excluded from the 
study.   
 
Preparation of genomic DNA 
Genomic DNA was extracted from whole blood obtained 
from each subject using a DNA Extractor WB-Rapid Kit (Wako, 
Osaka, Japan) according to the manufacturer’s protocol 
[10].   
 
Source of the genes and their polymorphisms 
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Three SNPs, nucleotide (nt) -538 G>A SNP (G-538A) in the 
promoter region, nt +7146 G>A SNP (G7146A) in intron 4, 
and nt +7785 C>T SNP (C7785T) in exon 5, in PDCD1 
(GenBank accession No.: NT_077995), located at 2q37.3, 
have been previously reported [17,19,21]. The adenine 
residue in the nucleotide sequence with respect to the 
transcriptional initiation site of this gene was numbered 
consecutively from +1.   
Two SNPs, rs2301756 in intron 3 and rs3741983 in 
intron 13, in PTPN11 (GenBank accession No.: NT_009775), 
located at 12q24.13, were selected using data available in 
the JSNP database (http://snp.ims.u-tokyo.ac.jp/) and the 
International HapMap database (http://www.hapmap.org/). 
The rs2301756 SNP in the International HapMap database is 
identical with JST057927 G-to-A in the JSNP database [30]. 
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The structures and positions of these SNPs sites in PDCD1 
and PTPN11 are shown in Figure 1. 
 
Determination of three SNPs in PDCD1   
The three SNPs, G-538A, G7146A, and C7785T, in PDCD1 
were determined by polymerase chain reaction 
(PCR)-restriction fragment length polymorphism. The 
polymorphic region was amplified by PCR with a GeneAmp 
PCR System 9700 thermal cycler (Applied Biosystems, 
Foster City, CA) using 20 ng of genomic DNA in a 25-µl 
reaction mixture containing 20 mM Tris-HCl (pH 8.4), 50 mM 
KCl, 1.5 mM MgCl
2
, 200 µM dNTPs, 15 pmol each of forward 
primer: 5’-GTGTGAGGCCATCCACAAG-3’ and reverse primer: 
5’-ACCCCACTCCCATTCTGTC-3’ for G-538A; forward primer: 
5’-GCAGAGGTGGAAGGACAGG-3’ and reverse primer: 
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5’-AGGCAGGCACACACATGG-3’ for G7146A; forward primer: 
5’-AGACGGAGTATGCCACCATTGTC-3’ and reverse primer: 
5’-AAATGCGCTGACCCGGGCTCAT-3’ for C7785T, and 1 U 
Taq DNA polymerase (Invitrogen, Carlsbad, CA). The 
amplification protocol consisted of initial denaturation at 
94C for 2 min, followed by 35 cycles of denaturation at 
94C for 30 sec, annealing for 30 sec at 60C for G-538A, 
63C for G7146A, and 62C for C7785T, and extension at 
72C for 30 sec, and final extension at 72C for 5 min. The 
PCR products were digested with Msp I (New England 
BioLabs Inc, Beverly, MA) for G-538A, Pst I (Invitrogen) for 
G7146A, and Pvu II (Takara Bio Inc., Kyoto, Japan) for 
C7785T. These digestion products were separated on a 6% 
polyacrylamide gel electrophoresis (Nacalai Tesque, Kyoto, 
Japan), and visualized with a UV transilluminator (Alpha 
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Innotech Co., San Leandro, CA) after ethidium bromide 
(Nacalai Tesque) staining. 
 
Determination of two SNPs in PTPN11   
The two SNPs, rs2301756 and rs3741983, in PTPN11 were 
also analyzed by the same method. The polymorphic region 
was amplified by PCR using 15 pmol each of forward primer: 
5’-CTGGTCTTGAACTCCTGGC-3’ and reverse primer: 
5’-GACTTGCCGTCATTGCTCTC-3’ for rs2301756; forward 
primer: 5’-GGTGCCAGAGTCTTTTCCAG-3’ and reverse 
primer: 5’-GCTCTGATCTCCACTCGTC-3’ for rs3741983. The 
other constituents of the PCR mixture and the amplification 
protocol were the same as described above except with the 
annealing temperature at 60C for rs2301756 and 62C for 
rs3741983. The PCR products were digested with Ban II 
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(Toyobo, Osaka, Japan) for rs2301756 and Mnl I (Fermentas 
International Inc., Ontario, Canada) for rs3741983. The 
digestion products were then separated by electrophoresis 
on a 2% agarose gel, and visualized as described above.   
 
Haplotype structure of PTPN11 
Subsequently, the two SNPs in PTPN11 were used for 
inference of the haplotype structure and for frequency 
analysis using SNP Alyze 7.0 standard (Dynacom Inc., 
Yokohama, Japan) to emphasize the variability and to 
enhance the power of detecting allelic association of rare 
variants. 
 
Statistical analysis   
Differences in age and gender between patients and control 
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subjects were evaluated by an unpaired Student's t-test and 
a chi-square test, respectively, using SPSS 15 (SPSS Japan 
Inc., Tokyo, Japan) and Prism 4 (GraphPad Software Inc., San 
Diego, CA). The frequencies of the expected alleles were 
calculated from those of the observed genotypes according 
to the Hardy-Weinberg equilibrium. The frequencies of 
observed and expected alleles were compared by a 
chi-square test with Yates' correction using SNP Alyze 7.0 
standard. The frequencies and distributions of alleles, 
genotypes, haplotypes, and diplotypes were compared 
between patients and control subjects by the chi-square test 
and logistic regression analysis using SPSS 15 and Prism 4. 
Odds ratios (OR) with 95% confidence intervals (CI) were 
calculated using SPSS 15. A P value of less than 0.05 was 
considered statistically significant. 
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Results   
Association of SNPs in PDCD1 with susceptibility to IBD  
The frequencies and distributions of alleles and genotypes 
at the three SNP sites in PDCD1 were identified and 
compared between UC or CD patients and control subjects 
(Tables II and III, respectively). G alleles at nt -538 and nt 
+7146 and the C allele at nt +7785 are major alleles, 
whereas the other alleles are minor alleles. The 
distributions of these SNPs in PDCD1 among IBD patients as 
well as control subjects corresponded well to the 
Hardy-Weinberg equilibrium, implying that our subject base 
has homogeneous genetic backgrounds. With respect to 
G7146A SNP, the A allele was not observed in the present 
study (Table II), supporting previous results to show that 
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this allele has been identified in the Caucasian and 
African-descent populations, but not in the Japanese 
population [33]. Furthermore, there were no significant 
differences in the frequencies of alleles and genotypes at 
the three SNP sites in PDCD1 between UC or CD patients and 
control subjects (Tables II and III). 
 
Association of SNPs in PTPN11 with susceptibility to IBD   
The frequencies and distributions of alleles and genotypes 
at the two SNP sites in PTPN11 were identified and 
compared between UC or CD patients and control subjects 
(Tables II and III, respectively). The G allele at rs2301756 
SNP and the T allele at rs3741983 SNP are major alleles, 
whereas the other alleles are minor alleles. The 
distributions of these SNPs in PTPN11 among IBD patients as 
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well as control subjects corresponded well to the 
Hardy-Weinberg equilibrium. A chi-square test revealed that 
the frequencies of the G allele at rs2301756 and the T allele 
at rs3741983 were significantly increased in patients with 
UC as compared with those in control subjects (84.6% vs. 
75.2%; P = 0.008 and 83.3% vs. 75.7%; P = 0.034, 
respectively) (Table II).   
 In addition, logistic regression analysis indicated 
that the frequencies of the G/G homozygous genotype at 
rs2301756 SNP and the T/T homozygous genotype at 
rs3741983 SNP were also significantly increased in patients 
with UC as compared with those in control subjects (71.1% 
vs. 57.5%; P = 0.018, OR = 1.814, 95% CI = 1.109 - 2.968 and 
68.4% vs. 56.0%; P = 0.031, OR = 1.702, 95% CI = 1.050 - 
2.761, respectively) (Table III). These results of the 
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genotype analyses regarding PTPN11 polymorphisms 
coincided well with those of the allele analyses between UC 
patients and control subjects. 
 
Association of haplotypes and diplotypes of PTPN11 with 
susceptibility to IBD   
Since a significant association was observed between allele 
and genotype polymorphisms at rs2301756 and rs3741983 
SNPs in PTPN11 and susceptibility to UC, four haplotypes 
composed of these two SNPs were constructed and 
identified using SNP Alyze 7.0 standard (Table IV). Logistic 
regression analyses revealed that the frequency of a 
haplotype, Hap 1 (G allele at rs2301756 and T allele at 
rs3741983), was significantly increased in patients with UC 
as compared with that in control subjects (82.9% vs. 74.0%, 
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P = 0.011, OR = 1.703, 95% CI = 1.129 - 2.568) (Table IV). 
Whereas, the frequency of another haplotype, Hap 2 (A 
allele at rs2301756 and C allele at rs3741983), was 
significantly decreased in UC patients as compared with 
that in control subjects (14.9% vs. 23.0%, P = 0.016, OR = 
0.587, 95% CI = 0.381 - 0.904) (Table IV). 
 Furthermore, 10 diplotypes composed of four 
haplotypes were identified (Table V). Logistic regression 
analysis showed that the frequency of the UC patients 
possessing a Hap 1/Hap 1 diplotype was significantly 
higher than that of control subjects (67.5% vs. 55.0%, P = 
0.030, OR = 1.703, 95% CI = 1.053 - 2.754) (Table V). 
However, a Hap 2/Hap 2 diplotype showed no statistically 
significant lack of susceptibility to UC (Table V). These 
results of the diplotype analysis regarding the Hap 1 
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haplotype of PTPN11 coincided well with those of the 




The present study is the first report to demonstrate an 
association between PTPN11 polymorphisms and 
susceptibility to UC in the Japanese population. The 
presence of the G allele and its homozygous G/G genotype 
at rs2301756 SNP, the T allele and its homozygous T/T 
genotype at rs3741983 SNP, the Hap 1 haplotype, and its 
homozygous Hap 1/Hap 1 diplotype in PTPN11 conferred 
susceptibility to UC. Inversely, the Hap 2 haplotype showed 
the statistically significant lack of susceptibility to UC. 
These findings imply that PTPN11 is a genetic determinant 
Narumi et al. 
 24
for predisposition to the onset of UC in Japanese 
individuals. However, the current study population was 
relatively small, and further study on a larger number of the 
Japanese population and on other ethnic populations is 
necessary to confirm the association between PTPN11 and 
UC.  
SHP-2, coded by PTPN11, is a key downstream 
molecule that downregulates T-cell and B-cell activation 
through interaction with CTLA4 and PD-1 [13-15,22-25]. 
SHP-2 is recruited to the phosphorylated tyrosine residue in 
the immunoreceptor tyrosine-based switch motif of the 
cytoplasmic tail of PD-1, and in the immunoreceptor 
tyrosine-based inhibitory motif of the cytoplasmic tail of 
CTLA4 [13-15,34,35]. Although the mechanisms of the 
PTPN11 polymorphisms identified in this study are 
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unknown, PTPN11 polymorphisms may affect the 
expression, affinity to immunoreceptors, and inhibitory 
activities of SHP-2, leading to the reduction in the SHP-2 
downregulatory effect on T-cell and B-cell activation. 
Another mechanism of inflammatory suppression is 
the downregulation of SHP-2 on the interleukin 6 
(IL-6)/signal transducer and activator of transcription 3 
(STAT3) signaling pathway through binding of SHP-2 to the 
receptor complex, glycoprotein 130 and IL-6 receptor alpha 
[36,37]. An increase in serum IL-6 concentrations and 
hyperactivation of STAT3 signaling have been reported in 
patients with IBD and experimental colitis in vivo [38-40]. 
Although the IL-6/STAT3 signaling is implicated in the 
pathogenesis of IBD, IL-6 expression and polymorphisms 
are associated with the progression and severity of IBD, but 
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not the onset [40-42]. These pathophysiological and genetic 
finings of IBD imply that the vicious pathway of T-cell 
activation driven by IL-6/STAT3 signaling can contribute to 
the perpetuation of chronic intestinal inflammatory process, 
probably resulting in the development of IBD. Thus, the 
reduction in the SHP-2 downregulatory effect against 
IL-6/STAT3 signaling due to its genetic polymorphisms may 
explain the progressing mechanism of IL-6-induced STAT3 
hyperactivation in IBD patients.  
Germline mutations of PTPN11 have been reported in 
patients with the autosomal dominant-inherited Noonan 
and LEOPARD syndromes [26-28], as well as somatic 
mutations in leukemogenesis [29]. These mutations are 
exclusively heterozygous missense mutations in exons 
containing the interacting portions of the amino terminal 
Narumi et al. 
 27
src homology 2 and protein tyrosine phosphatase domains, 
which introduce amino acid substitutions, leading to the 
gain-of-function of SHP-2 [43,44]. On the other hand, an 
intronic polymorphism (rs2301756 SNP in intron 3 of 
PTPN11), but not an exonic mutation, is associated with 
gastric atrophy in Japanese individuals infected with 
cagA-positive H. pylori [30], indicating persistent chronic 
inflammation in epithelial cells of the stomach in the 
individuals possessing the G/A genotype at the rs2301756 
SNP site in PTPN11. Atrophy of the gastric mucosae is the 
endpoint of chronic diseases, and is often found in patients 
with chronic gastritis with H. pylori infection. Likewise, 
since persistent chronic inflammation in epithelial cells of 
the colon contributes to the pathogenesis of UC, chronic 
inflammation due to PTPN11 polymorphisms in the gastric 
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and colon mucosae may be explained by the same 
mechanism. Thus, from the pathophysiological perspective, 
we speculate that intronic polymorphisms, especially 
possessing the Hap 1 haplotype and its homozygous Hap 
1/Hap 1 diplotype, may interfere with gene expression. This 
causes a reduction of SHP-2 mRNA and protein levels, 
subsequently leading to the loss-of-function of SHP-2, 
which is in contrast to the gain-of-function of SHP-2 caused 
by exonic missense mutations of PTPN11. Therefore, the 
accumulation of altering the loss-of-function of SHP-2 
caused by PTPN11 polymorphisms may lead to the 
reduction in the inhibitory effects against T-cell and B-cell 
activation, resulting in persistent chronic intestinal 
inflammation and the onset of UC.  
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Conclusions 
As PTPN11 is a genetic determinant for susceptibility to UC 
in the Japanese population, intronic polymorphisms of 
PTPN11 may be useful as new DNA-based biomarkers for 
identifying individuals at high-risk for UC. Moreover, SHP-2 
may be a good target molecule for novel drugs discovery. 
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Figure Legends 
Figure 1: Locations of the SNP sites in PDCD1 (A) and PTPN11 
(B). The horizontal bars indicate the genomic sequence of 
PDCD1 (A) and of PTPN11 (B). Rectangles represent exons in 
each gene and exon numbers are indicated above each exon. 
Arrows indicate the positions of the SNP sites.  
ATG: transcriptional initiation site.  
TGA: stop codon site. 
 
Table I   Clinical characteristics of study subjects 
Control subjects
UC (n = 114) CD (n = 83) (n = 200)
Age, mean ± SD
(years)
44.2 ± 16.7* 34.3 ± 12.5 32.5 ± 11.2
Age range (years) 14-83 17-75 20-60
Male/female (%) 59/55 (51.7/48.3) 50/33 (60.2/39.8) 126/74 (62.5/37.5)




Table II   Distributions of alleles at the SNP sites in each gene among study subjects 
Allele comparison* Allele comparison*
UC Control P value CD Control P  value
PDCD1 G-538A G 121 (53.1) 206 (51.5) 84 (50.6) 206 (51.5)
A 107 (46.9) 194 (48.5) 82 (49.4) 194 (48.5)
G7146A G 228 (100) 400 (100) 166 (100) 400 (100)
A 0 0 0 0
C7785T C 152 (66.7) 264 (66.0) 152 (66.7) 264 (66.0)
T 76 (33.3) 136 (34.0) 76 (33.3) 136 (34.0)
PTPN11 rs2301756 A 35 (15.4) 99 (24.8) 36 (21.7) 99 (24.8)
G 193 (84.6) 301 (75.2) 130 (78.3) 301 (75.2)
rs3741983 C 38 (16.7) 97 (24.3) 36 (21.7) 97 (24.3)
T 190 (83.3) 303 (75.7) 130 (78.3) 303 (75.7)
Total number of alleles 228 400 166 400















Table III   Distributions of genotypes at the SNP sites in each gene among study subjects 
UC Control OR (95% CI) P value CD Control OR (95% CI) P value
PDCD1 G-538A G/G 33 (28.9) 55 (27.5) 1.074 (0.645 - 1.789) 0.784 18 (21.7) 55 (27.5) 0.730 (0.398 - 1.340) 0.310
G/A 55 (48.2) 96 (48.0) 1.010 (0.637 - 1.600) 0.967 48 (57.8) 96 (48.0) 1.486 (0.886 - 2.490) 0.133
A/A 26 (22.8) 49 (24.5) 0.910 (0.529 - 1.568) 0.735 33 (39.8) 49 (24.5) 0.794 (0.426 - 1.480) 0.467
G+7146A G/G 114 (100) 200 (100) – – 83 (100) 200 (100) – –
G/A 0 0 – – 0 0 – –
A/A 0 0 – – 0 0 – –
C+7785T C/C 54 (47.4) 87 (43.5) 1.169 (0.737 - 1.855) 0.508 39 (47.0) 87 (43.5) 1.151 (0.689 - 1.924) 0.591
C/T 44 (38.6) 89 (44.5) 0.768 (0.481 - 1.228) 0.270 37 (44.6) 89 (44.5) 0.983 (0.588 - 1.645) 0.948
T/T 16 (14.0) 23 (11.5) 1.256 (0.634 - 2.490) 0.513 7 (8.4) 23 (11.5) 0.709 (0.292 - 1.722) 0.447
PTPN11rs2301756 A/A 2 (1.8) 14 (7.0) 0.237 (0.053 - 1.063) 0.060 7 (8.4) 14 (7.0) 1.224 (0.475 - 3.151) 0.676
A/G 31 (27.2) 71 (35.5) 0.679 (0.410 - 1.123) 0.132 22 (26.5) 71 (35.5) 0.655 (0.372 - 1.155) 0.144
G/G 81 (71.1) 115 (57.5) 1.814 (1.109 - 2.968) 0.018 54 (65.1) 115 (57.5) 1.376 (0.809 - 2.341) 0.239
rs374198
3
C/C 2 (1.8) 9 (4.5) 0.379 (0.080 - 1.785) 0.220 6 (7.2) 9 (4.5) 1.654 (0.569 - 4.803) 0.355
C/T 34 (29.8) 79 (39.5) 0.651 (0.398 - 1.064) 0.087 24 (28.9) 79 (39.5) 0.623 (0.358 - 1.083) 0.093
T/T 78 (68.4) 112 (56.0) 1.702 (1.050 - 2.761) 0.031 53 (63.9) 112 (56.0) 1.388 (0.819 - 2.353) 0.223
Total number of subjects 114 200 83 200
*Each genotype was compared with other genotypes combined by logistic regression analysis.
OR: odds ratio; CI: confidence interval




Number (%) of genotype
Table IV   Distributions of haplotypes in PTPN11  among study subjects
rs2301756rs3741983 UC Control OR (95% CI) P value CD Control OR (95% CI) P value
Hap 1 G T 189 (82.9) 296 (74.0) 1.703 (1.129 - 2.568) 0.011 125 (75.3) 296 (74.0) 1.071 (0.706 - 1.626) 0.747
Hap 2 A C 34 (14.9) 92 (23.0) 0.587 (0.381 - 0.904) 0.016 31 (18.7) 92 (23.0) 0.769 (0.488 - 1.211) 0.257
Hap 3 G C 4 (1.8) 5 (1.3) 1.411 (0.375 - 5.307) 0.611 5 (3.0) 5 (1.3) 2.453 (0.701 - 8.590) 0.160
Hap 4 A T 1 (0.4) 7 (1.8) 0.247 (0.030 - 2.023) 0.193 5 (3.0) 7 (1.8) 1.744 (0.545 - 5.574) 0.348
Total number of haplotypes 228 400 166 400
*Each haplotype was compared with other haplotypes combined by logistic regression analysis.
OR: odds ratio; CI: confidence interval
Haplotype comparison*SNPHaploty
pe
Number (%) of haplotypes Haplotype comparison* Number (%) of haplotypes
Table V   Distributions of diplotypes of PTPN11  among study subjects
UC Control OR (95% CI) P value CD Control OR (95% CI) P  value
Hap 1 / Hap 1 77 (67.5) 110 (55.0) 1.703 (1.053 - 2.754) 0.030 50 (60.2) 110 (55.0) 1.24 (0.737 - 2.086) 0.418
Hap 1 / Hap 2 30 (26.3) 69 (34.5) 0.678 (0.408 - 1.128) 0.134 21 (25.3) 69 (34.5) 0.643 (0.362 - 1.142) 0.132
Hap 1 / Hap 3 4 (3.5) 5 (2.5) 1.418 (0.373 - 5.391) 0.608 3 (3.6) 5 (2.5) 1.463 (0.341 - 6.265) 0.609
Hap 1 / Hap 4 1 (0.9) 2 (1.0) 0.876 (0.079 - 9.770) 0.914 1 (1.2) 2 (1.0) 1.207 (0.108 - 13.499) 0.878
Hap 2 / Hap 2 2 (1.8) 9 (4.5) 0.379 (0.080 - 1.785) 0.220 5 (6.0) 9 (4.5) 1.360 (0.442 - 4.188) 0.592
Hap 2 / Hap 3 0 0 - - 0 0 - -
Hap 2 / Hap 4 0 5 (2.5) - - 0 5 (2.5) - -
Hap 3 / Hap 3 0 0 - - 1 (1.2) 0 - -
Hap 3 / Hap 4 0 0 - - 0 0 - -
Hap 4 / Hap 4 0 0 - - 2 (2.4) 0 - -
114 200 83 200
*Each diplotype was compared with other diplotypes combined by logistic regression analysis.
OR: odds ratio; CI: confidence interval
Diplotype comparison*
Diplotype
Number (%) of diplotypes Diplotype comparison* Number (%) of diplotypes
Total number of subjects
(A) PDCD1
(B) PTPN11 
Figure 1: Locations of the SNP sites in PDCD1 and PTPN11
